PE20011229A1 - 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato - Google Patents

4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato

Info

Publication number
PE20011229A1
PE20011229A1 PE2001000359A PE2001000359A PE20011229A1 PE 20011229 A1 PE20011229 A1 PE 20011229A1 PE 2001000359 A PE2001000359 A PE 2001000359A PE 2001000359 A PE2001000359 A PE 2001000359A PE 20011229 A1 PE20011229 A1 PE 20011229A1
Authority
PE
Peru
Prior art keywords
piperidin
phenoxy
diol
benzyl
hydroxy
Prior art date
Application number
PE2001000359A
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Rene Wyler
Marie-Paule Heitz Neidhart
Emmanuel Pinard
Georg Jaeschke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20011229A1 publication Critical patent/PE20011229A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

SE REFIERE A 4-BENCIL-1-[2-(4-HIDROXI-FENOXI)-ETIL]-PIPERIDIN-3,4-DIOL DE FORMULA I SUS ENANTIOMEROS R,R-; S,S- COMO (4R,3R) Y (4S,3S)-4-BENCIL-1-[2-(4-HIDROXI-FENOXI)-ETIL]-PIPERIDIN-3,4-DIOL. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES BLOQUEADOR SELECTIVO DE SUBTIPOS DE RECEPTOR N-METIL-D-ASPARTATO (NMDA) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE FORMAS AGUDAS DE NEURODEGENERACION CAUSADAS POR APOPLEJIA O TRAUMAS CEREBRALES, FORMAS CRONICAS DE NEURODEGENERACION COMO ALZHEIMER, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, ESCLEROSIS LATERAL AMIOTROFICA, NEURODEGENERACION ASOCIADA A INFECCIONES BACTERIANAS OVIRICAS, ESQUIZOFRENIA, ANSIEDAD, DEPRESION, DOLOR CRONICO AGUDO
PE2001000359A 2000-04-25 2001-04-19 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato PE20011229A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25

Publications (1)

Publication Number Publication Date
PE20011229A1 true PE20011229A1 (es) 2001-12-08

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000359A PE20011229A1 (es) 2000-04-25 2001-04-19 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato

Country Status (18)

Country Link
US (1) US6432985B2 (es)
EP (1) EP1278730B1 (es)
JP (1) JP3831255B2 (es)
KR (1) KR100527527B1 (es)
CN (1) CN1178914C (es)
AR (1) AR028357A1 (es)
AT (1) ATE313527T1 (es)
AU (1) AU785153B2 (es)
BR (1) BR0110233A (es)
CA (1) CA2407345C (es)
DE (1) DE60116080T2 (es)
DK (1) DK1278730T3 (es)
ES (1) ES2254422T3 (es)
MX (1) MXPA02010573A (es)
PE (1) PE20011229A1 (es)
UY (1) UY26681A1 (es)
WO (1) WO2001081309A2 (es)
ZA (1) ZA200208134B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
JP2011516417A (ja) * 2008-03-27 2011-05-26 エヴォテック・ノイロサイエンシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｎｍｄａｎｒ２ｂ−サブタイプ選択的アンタゴニストを使用する障害の処置方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
BRPI0917948A2 (pt) 2008-08-12 2017-06-20 Zinfandel Pharrmaceuticals Inc métodos de identificar uma variante genética que está associada com o desenvolvimento de uma condição de interesse e um paciente em um ensaio clínico de um tratamento para doença de alzheimer, de determinar riscos incrementando de desenvolvimento de uma condição de interesse, doença de alzheimer em um paciente, de um prognóstico ou o risco de desenvolver doença de alzheimer em um paciente, de tratar um paciente para doença de alzheimer, uma condição de interesse e doença de alzheimer em um paciente, de estratificar um paciente em um subgrupo de um ensaio clínico de uma terapia para o tratamento de doença de alzheimer, uso de um agente ativo anti-doença de alzheimer e kits para determinar se um paciente encontra-se em risco incrementado de desenvolver doença de alzheimer e se um paciente é responsivo a tratamento para uma condição de interesse
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN109790149B (zh) * 2016-11-08 2022-05-17 豪夫迈·罗氏有限公司 苯氧基三唑类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
CN1178914C (zh) 2004-12-08
UY26681A1 (es) 2001-10-25
BR0110233A (pt) 2003-01-21
CA2407345C (en) 2009-04-07
WO2001081309A2 (en) 2001-11-01
ATE313527T1 (de) 2006-01-15
EP1278730A2 (en) 2003-01-29
AR028357A1 (es) 2003-05-07
KR100527527B1 (ko) 2005-11-09
ES2254422T3 (es) 2006-06-16
JP2004509837A (ja) 2004-04-02
DE60116080D1 (de) 2006-01-26
CN1443166A (zh) 2003-09-17
US6432985B2 (en) 2002-08-13
DK1278730T3 (da) 2006-05-01
ZA200208134B (en) 2004-01-22
EP1278730B1 (en) 2005-12-21
DE60116080T2 (de) 2006-08-24
AU785153B2 (en) 2006-10-05
WO2001081309A3 (en) 2002-01-17
AU6021301A (en) 2001-11-07
JP3831255B2 (ja) 2006-10-11
MXPA02010573A (es) 2003-03-10
KR20040007216A (ko) 2004-01-24
CA2407345A1 (en) 2001-11-01
US20010047014A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
PE20011229A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol como bloqueadores del receptor n-metil-d-aspartato
DOP2011000135A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
RS98504A (en) (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
NZ595571A (en) Pyrazole compounds and uses thereof
UY29927A1 (es) Derivados sustituidos de la 5-fenil-2-tioxo-imidazolin-4-ona y de la 5-fenil-2-amino-imidazolidin-4-ona y sus sales, composiciones y aplicaciones
NZ590887A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
CY1110316T1 (el) Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους
EP2098515A4 (en) SUBSTITUTED CARBINOL COMPOUNDS
CA2495960A1 (fr) Nouveau procede de synthese du (7-methoxy-1-naphtyl)acetonitrile et application a la synthese de l'agomelatine
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
AR054779A1 (es) N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida
JP2004509837A5 (es)
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
BRPI0615614A2 (pt) compostos orgánicos
PA8496601A1 (es) Derivados de piperidin - etansulfonil
PE20081664A1 (es) Derivados de azabicicloalcano, su preparacion y su aplicacion en terapeutica
BR0112609A (pt) Derivados de anilina
ECSP003519A (es) Derivados de etanosulfonilo-piperidina
PE20000955A1 (es) El uso de derivados de aril-ciclohexilamina contra desordenes del sistema nervioso central
BR112023002013A2 (pt) Formas cristalinas de um inibidor de o-glicoproteína-2-acetamido-2-desóxi-3-d-glucopiranosidase
DOP2004000983A (es) Antagonistas 4-cicloalquilaminopirazol pirimidina de nmda/nr2b
BRPI0506557A (pt) uso do metronidazol para a preparação de uma composição farmacêutica

Legal Events

Date Code Title Description
FD Application declared void or lapsed